Home › Research › Biomarkers
Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders
Isabel Schulz, Niels Kruse, Roland G Gera, Thomas Kremer, Jesse Cedarbaum, Robin Barbour, Wagner Zago, Sebastian Schade et al.. Movement disorders : official journal of the Movement Disorder Society, 2021-08-07
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
CSF total aSyn was decreased. NfL, pNfH, UCHL-1, GFAP, S100B, and sTREM-2 were increased in patients with neurodegenerative disease versus HC (P < 0.05). As expected, some of the markers were highest in AD (i.e., UCHL-1, GFAP, S100B, sTREM-2, YKL-40). Within ASRD, CSF NfL levels were higher in MSA than PD and DLB (P < 0.05). Comparing PD to HC, interesting serum markers were S100B (AUC: 0.86), sTREM2 (AUC: 0.87), and NfL (AUC: 0.78). CSF S100B and serum GFAP were highest in DLB. Levels of most marker candidates tested in serum and CSF significantly differed between disease groups and HC. In the stratification of PD versus other tau- or aSyn-related conditions, CSF NfL levels best discriminated PD and MSA. CSF S100B and serum GFAP best discriminated PD and DLB. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Schulz, I., Kruse, N., Gera, R. G., Kremer, T., Cedarbaum, J., Barbour, R., et al. (2021). Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders. Movement disorders : official journal of the Movement Disorder Society. https://doi.org/10.1002/mds.28738
Vancouver
Schulz I, Kruse N, Gera RG, Kremer T, Cedarbaum J, Barbour R, et al. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders. Movement disorders : official journal of the Movement Disorder Society. 2021. doi:10.1002/mds.28738. PMID: 34363416.
BibTeX
@article{schulz2021-34363416,
author = {Schulz, Isabel and Kruse, Niels and Gera, Roland G and Kremer, Thomas and Cedarbaum, Jesse and Barbour, Robin and Zago, Wagner and Schade, Sebastian and others},
title = {{Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders}},
journal = {Movement disorders : official journal of the Movement Disorder Society},
year = {2021},
doi = {10.1002/mds.28738},
pmid = {34363416},
url = {https://doi.org/10.1002/mds.28738}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- NfL, pNfH, UCHL-1, GFAP, S100B, and sTREM-2 were increased in patients with neurodegenerative disease versus HC (P < 0.05).
- As expected, some of the markers were highest in AD (i.e., UCHL-1, GFAP, S100B, sTREM-2, YKL-40).
- Within ASRD, CSF NfL levels were higher in MSA than PD and DLB (P < 0.05).
- Comparing PD to HC, interesting serum markers were S100B (AUC: 0.86), sTREM2 (AUC: 0.87), and NfL (AUC: 0.78).
- CSF S100B and serum GFAP were highest in DLB.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants151
- Effect sizeAUC: 0.86; AUC: 0.87; AUC: 0.78
- Evidence strengthModerate
How this study scored 59/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 33 of the 56 points we could judge it on, which is 59 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Movement disorders : official journal of the Movement Disorder Society) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 151 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34363416) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 33 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 33 of the 56 points we could judge it on is 59 out of 100. |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also in Biomarkers
137 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.